Emerging amyloid and tau targeting treatments for Alzheimer's disease.

about

Anti-β-sheet conformation monoclonal antibody reduces tau and Aβ oligomer pathology in an Alzheimer's disease model.Synaptic dysfunction in Alzheimer's disease: the effects of amyloid beta on synaptic vesicle dynamics as a novel target for therapeutic intervention.

P2860

Q47833979-FD7631B1-5EF6-4A3E-BBEF-F97B2120A321 Q53513746-2282E782-62A2-455B-8758-78E9624C6CE4

P2860

Emerging amyloid and tau targeting treatments for Alzheimer's disease.

Item

http://www.wikidata.org/entity/Q39296311

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Emerging amyloid and tau targeting treatments for Alzheimer's disease.

@en

Emerging amyloid and tau targeting treatments for Alzheimer's disease.

@nl

type

Item

label

Emerging amyloid and tau targeting treatments for Alzheimer's disease.

@en

Emerging amyloid and tau targeting treatments for Alzheimer's disease.

@nl

prefLabel

Emerging amyloid and tau targeting treatments for Alzheimer's disease.

@en

Emerging amyloid and tau targeting treatments for Alzheimer's disease.

@nl

P1476

Emerging amyloid and tau targeting treatments for Alzheimer's disease.

@en

P2093

Ayesha Khan

http://www.w3.org/2001/XMLSchema#string

P2860

Complex Disposition of Methylthioninium Redox Forms Determines Efficacy in Tau Aggregation Inhibitor Therapy for Alzheimer's Disease

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines

Allopregnanolone reverses neurogenic and cognitive deficits in mouse model of Alzheimer's disease

Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study

Methylene blue reduces aβ levels and rescues early cognitive deficit by increasing proteasome activity

Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

An atomic structure of human γ-secretase

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

P304

697-711

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14737175.2017.1326819

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Clive Ballard

Anne Corbett

P577

2017-05-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28490214

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

Emerging amyloid and tau targeting treatments for Alzheimer's disease.

about

P2860

P2860

Emerging amyloid and tau targeting treatments for Alzheimer's disease.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921